Published May 11, 2021 in the journal Drug Science, this study of 900 medical cannabis patients in the UK showed clinically significant improvements in the Quality of Life ratings (EQ-5D-5L) of patients with Chronic Pain, MS, Tourette's Syndrome, Epilepsy, & PTSD.
There was a remarkable increase of 51% in patients quality of life scores, and there were "significant improvements in patients' ability to manage debilitating secondary conditions such as anxiety, insomnia, and depression."
One unique aspect of this observational study was that it studied patients with "multiple pathologies" (conditions). These types of patients are excluded from traditional randomized clinical trials, so this type of study is about the only way to develop actionable knowledge for them.
The article in Drug Science is here.